Scynexis (SCYX) Shares Outstanding (2013 - 2026)
Scynexis' (SCYX) quarterly Shares Outstanding (Entity) came in at $9.9 million in Q2 2026, up 60.0% on a YoY basis from $6.2 million in Q2 2025, and up 56.2% quarter-over-quarter from $6.4 million in Q1 2026.
Analysis
Scynexis (SCYX) Shares Outstanding (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Shares Outstanding (Entity) for 14 consecutive years, with $9.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 60.0% year-over-year to $9.9 million; the trailing twelve-month figure through Jun 2026 stood at $9.9 million (up 60.0% YoY), and the FY2025 full-year result was $5.4 million, down 10.25% from the prior year.
- Shares Outstanding (Entity) advanced to $9.9 million in Q2 2026 per SCYX's latest filing, from $6.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $9.9 million in Q2 2026 and bottomed at $3.7 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $6.0 million across 5 years, with a median of $6.0 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) surged 98.88% in 2022, then declined 13.7% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $5.3 million in 2022, then rose by 12.29% to $6.0 million in 2023, then increased by 1.38% to $6.1 million in 2024, then slipped by 10.25% to $5.4 million in 2025, then surged by 82.81% to $9.9 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $9.9 million, $6.4 million, and $5.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 11.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.82 Mn |
| Mar 31, 2026 | 6.37 Mn |
| Dec 31, 2025 | 6.24 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Mar 31, 2025 | 6.18 Mn |
| Dec 31, 2024 | 6.06 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 6.03 Mn |
| Dec 31, 2023 | 5.98 Mn |
| Sep 30, 2023 | 5.99 Mn |
| Jun 30, 2023 | 5.98 Mn |
| Mar 31, 2023 | 5.97 Mn |
| Dec 31, 2022 | 5.33 Mn |
| Sep 30, 2022 | 5.94 Mn |
| Jun 30, 2022 | 5.41 Mn |
| Mar 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 3.30 Mn |
| Sep 30, 2021 | 3.33 Mn |